ORLANDO, Fla., March 10, 2011 /PRNewswire/ -- Today, the nation's most prestigious minds in prostate cancer research unveiled the findings of their groundbreaking studies at the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Florida.
Leading prostate cancer clinicians, researchers, and consumer advocates (prostate cancer survivors) formed a unified front against the ravages of prostate cancer through their studies and stories at one of the largest prostate cancer research conferences in the U.S. These findings are key developments in translating laboratory research into new and more effective treatments for men and their families affected by prostate cancer.
Featured press conference presenters include:
- Dr. Lionel L. Banez, Assistant Professor of Urology in the Division of Urologic Surgery, Department of Surgery at Duke University Medical Center, and Director of the Duke Prostate Center Outcomes Database.
- Mr. Joel Nowak, Prostate Cancer Consumer Advocate, Malecare.
- Dr. Folakemi Odedina, Professor of Pharmaceutical Outcomes and Policy, and Director of Community Outreach and Minority Affairs at the University of Florida.
- Dr. Brian Olson, Fellow at the University of Wisconsin, Madison, whose research includes tumor immunology with a focus on vaccine development.
- Dr. Howard I. Scher, Chief of the Genitourinary Oncology Service and Professor of Medicine, Memorial Sloan-Kettering Cancer Center.
In an exclusive press conference, scientists and clinicians spoke of the exciting developments in their work. Key studies include:
In another study, researchers revealed that men who take a certain class of cholesterol-lowering medicine, otherwise known as statins, may be 60 percent less likely to be diagnosed with high-grade prostate cancer. Involving more than 55,000 men, this study offers an exciting understanding of prostate cancer prevention.
Scientists are also expanding our understanding of the cancer migration process by examining specific molecules and how they stimulate the migration of prostate cancer cells. This increased knowledge is paving the way for the next steps toward effective therapeutic treatments for prostate cancer patients.
Other researchers revealed an alarming disparity in prostate cancer knowledge among African American men, a population suffering from the highest incidence rate for prostate cancer among all racial and ethnic groups. Researchers look to assess the information gap that appears to exist by following newly diagnosed African American and Caucasian men on their journey toward treatment. In another study, modifiable prostate cancer risk reduction and early detection behaviors among African American men were discussed.
About the PCRP and IMPaCT Conference
The Department of Defense Prostate Cancer Research Program (PCRP) is the second-largest funder of prostate cancer research in the U.S. The program brings together prestigious prostate cancer researchers, survivors, and policy makers to tackle research challenges and offer hope to the millions of people affected directly and indirectly by prostate cancer. The IMPaCT conference represents an unparalleled collaboration between the research community and prostate cancer survivors and advocates—making the PCRP successful in identifying innovative research that tackles prostate cancer's most critical issues.
Contact: Kristi Betz
SOURCE Department of Defense Prostate Cancer Research Program